Experience Leucine AI.
Powered Pharma Operations

Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.

See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.

Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.

Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.

Optimize your manufacturing processes with paperless operations
Strengthen quality management and regulatory compliance
Accelerate laboratory operations and testing workflows

Connect with a Leucine Expert

Schedule a 30-Minute Product Demo with Expert Q&A

Sub System
Laboratory Controls

Laboratory Controls

View Detailed Analysis

Analytics Overview

67
Form 483s Issued
9
483s converted to WL
88
Total Observation
Form 483s Issued
+74 from last period

Analytics Overview

Form 483 Conversion Rate by Year
Form 483s Issued (Yearly)

Recent Form 483s & Warning Letters

View all 483’s
Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
19 Nov 2024
Dr. Reddy's Laboratories Limited (Unit II)
Drugs
25 Oct 2024
OSRX Inc.
Drugs
27 Sep 2024
RC Outsourcing, LLC
Drugs
28 Aug 2024
Empower Pharmacy
Drugs
16 Aug 2024
Belcher Pharmaceuticals, LLC
Drugs

Top Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Justin A Boyd
18
3
Anastasia M Shields
10
1
Patty P Kaewussdangkul
5
3
Arsen Karapetyan
5
1
Pratik S Upadhyay
5
2
TITLE/ COMPANY Issue Date Status Details
You have not established Laboratory controls that include the establishment of scientifically sound and appropriate specifications
Dr. Reddy's Laboratories Limited (Unit II)
19 Nov 2024 Normal Justification: Observation highlights failure in laboratory controls, evident from lack of stability testing and revalidation omissions.
Excerpt: An on-going testing program to monitor the stability characteristics of APIs is not established and followed.
View Details
Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements
OSRX Inc.
25 Oct 2024 Normal Justification: Sterility testing, a critical laboratory control, was not verified before product release, compromising quality.
Excerpt: sterility testing being completed by your third party laboratory as documented...
View Details
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications
RC Outsourcing, LLC
27 Sep 2024 Normal Justification: Laboratory controls play a crucial role in ensuring product conformity to quality standards. This observation highlights discrepancies in this area.
Excerpt: Your firm failed to provide scientific rationale to support established limits for subvisible particles in Avastin.
View Details
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications and test procedures
Empower Pharmacy
28 Aug 2024 Normal Justification: The issue stems from inadequate laboratory controls which are fundamental for proper testing and documentation, as highlighted in the observation.
Excerpt: Laboratory controls do not include the establishment of scientifically sound and appropriate specifications and test procedures.
View Details
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.
Belcher Pharmaceuticals, LLC
16 Aug 2024 Normal Justification: Observations point to deficiencies in laboratory control procedures leading to oversight in impurity testing.
Excerpt: Your firm failed to conduct testing for impurities as part of your finished product specification requirements prior to batch release.
View Details

Prepare Better for FDA Audits with FDA Tracker

Get Real-time Insights: FDA 483s & Warning letters.
Uncover Trends: FDA Investigator profiles & Observations.
Stay Compliant: Manage risks proactively.